Innovative Interventions for Smoking Cessation: Comparison of Very Low Nicotine Content Cigarettes Plus Nicotine Patch; Very Low Nicotine Content Cigarettes Alone or Nicotine Patch Alone
Overview
- Phase
- Phase 2
- Intervention
- VLNC Cigarette
- Conditions
- Tobacco Use Disorder
- Sponsor
- University of Minnesota
- Enrollment
- 235
- Locations
- 2
- Primary Endpoint
- End of Follow-up Abstinence Rates
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content (VLNC) cigarettes compared to 21 mg nicotine patch only and very low nicotine content cigarette only on abstinence, time to relapse and toxicant levels. The study will determine if adding nicotine replacement medication to the very low content cigarettes (VLNC) will augment treatment compared to nicotine patch only or to very low nicotine content cigarettes only.
Detailed Description
The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content cigarette (VLNC) compared to the VLNC cigarette alone or 21 mg nicotine patch alone on abstinence, time to relapse and toxicant levels. The following primary hypothesis will be tested: Abstinence rates will be highest and the time to relapse will be the longest in the VLNC cigarettes plus nicotine patch condition compared to nicotine patch or VLNC cigarettes alone. Other hypotheses include: 1. Greater positive subjective responses to cigarettes will be observed with VLNC cigarettes plus patch vs. VLNC cigarette; 2. Less drop-outs will be observed in the VLNC plus patch vs the other two conditions; and 3. Less compensatory smoking will be observed in the VLNC plus patch condition compared to VLNC cigarette alone condition. Cigarette smokers will be randomized to: 1. VLNC cigarettes (which provide sensory behavioral aspects of smoking but with limited nicotine) plus nicotine patch for 6 weeks; 2. Nicotine patch for 6 weeks; or 3. VLNC cigarettes alone. Outcome measures will include cessation assessed at the end of treatment as the primary endpoint and at 36 weeks post-treatment, time to lapse and relapse to usual brand cigarettes, and biomarkers of toxicant exposure. Predictors of abstinence and treatment response for each of the treatment conditions will be explored.
Investigators
Eligibility Criteria
Inclusion Criteria
- •a) Smoking at least 10 cigarettes daily for the past year;
- •b) In good physical health;
- •c) No contraindications for medicinal nicotine; and
- •d) Stable, good mental health.
Exclusion Criteria
- •a) Subjects must not be using other tobacco or nicotine products.
- •b) Female subjects cannot be pregnant or nursing and must be using appropriate birth control.
Arms & Interventions
VLNC Cigarette
Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
Intervention: VLNC Cigarette
Nicotine Patch
21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
Intervention: Nicotine Patch
VLNC Cigarette plus Nicotine Patch
Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks
Intervention: VLNC Cigarette Plus Nicotine Patch
Outcomes
Primary Outcomes
End of Follow-up Abstinence Rates
Time Frame: 36 weeks
CO- and cotinine-verified point prevalence abstinence
End of Treatment Abstinence Rate
Time Frame: 12 week
Cotinine and carbon monoxide (CO) verified point prevalence abstinence
Secondary Outcomes
- Exposure to Tobacco Toxicants(6 weeks)
- Time to Lapse or Relapse to Tobacco Use(26 weeks)